Abstract
Spingolipids (SLs) are an important component of central nervous system (CNS) myelin sheaths and affect the viability of brain cells (oligodendrocytes, neurons and astrocytes) that is determined by signaling mediated by bioactive sphingoids (lyso-SLs). Recent studies indicate that two lipids, ceramide and sphingosine 1-phosphate (S1P), are particularly involved in many human diseases including the autoimmune inflammatory demyelination of multiple sclerosis (MS). In this review we: (1) Discuss possible sources of ceramide in CNS; (2) Summarize the features of the metabolism of S1P and its downstream signaling through G-protein-coupled receptors; (3) Link perturbations in bioactive SLs metabolism to MS neurodegeneration and (4) Compile ceramide and S1P relationships to this process. In addition, we described recent preclinical and clinical trials of therapies targeting S1P signaling, including 2-amino-2-propane-1,3-diol hydrochloride (FTY720, fingolimod) as well as proposed intervention to specify critical SL levels that tilt balances of apoptotic/active ceramide versus anti-apoptotic/inactive dihydroceramide that may offer a novel and important therapeutic approach to MS.
Similar content being viewed by others
Abbreviations
- ASMase:
-
Acid sphingomyelinase
- CDase:
-
Ceramidase
- Cer:
-
Ceramide
- Cer1P:
-
Ceramide 1-phosphate
- CerS:
-
Ceramide synthase (N-acyl transferase)
- CNS:
-
Central nervous system
- CSF:
-
Cerebrospinal fluid
- DES:
-
Dihydroceramide desaturase
- DHSph:
-
Dihydrosphingosine
- EAE:
-
Experimental autoimmune encephalomyelitis
- GalCer:
-
Galactosylceramide
- GalCerS:
-
Galactosylceramide synthase
- GlcCer:
-
Glucosylceramide
- GlcCerC:
-
Glucosylceramide synthase
- GM:
-
Gray matter
- GSL:
-
Glycosphingolipid
- KDHR:
-
3-keto-dihydrosphingosine reductase
- KDHSph:
-
3-keto-dihydrosphingosine
- MS:
-
Multiple sclerosis
- NAWM:
-
Normal appearing white matter
- NSMase:
-
Neutral sphingomyelinase
- S1P:
-
Sphingosine 1-phosphate
- SM:
-
Sphingomyelin
- SMase:
-
Sphingomyelinase
- SMS:
-
Sphingomyelin synthase
- SpH:
-
Sphingosine
- SphK1:
-
Sphingosine kinase 1
- SphK2:
-
Sphingosine kinase 2
- Spl:
-
Sphingosine 1-phosphate lyase
- SPP1:
-
Sphingosine 1-phosphate phosphatase 1
- SPP2:
-
Sphingosine 1-phosphate phosphatase 2
- SPT:
-
Serine palmitoyltransferase
References
Frohman EM, Racke MK, Raine CS (2006) Multiple sclerosis–the plaque and its pathogenesis. N Engl J Med 354(9):942–955
Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343(13):938–952
Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47(6):707–717
Franklin RJ (2002) Why does remyelination fail in multiple sclerosis? Nat Rev Neurosci 3(9):705–714
Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338(5):278–285
von Herrath MG, Fujinami RS, Whitton JL (2003) Microorganisms and autoimmunity: making the barren field fertile? Nat Rev Microbiol 1(2):151–157
Wucherpfennig KW (2001) Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 108(8):1097–1104
Podbielska M, Hogan EL (2009) Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis? Mult Scler 15(9):1011–1029
Chun J, Hartung HP (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33(2):91–101
Ishii I, Fukushima N, Ye X, Chun J (2004) Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 73:321–354
Zheng W, Kollmeyer J, Symolon H, Momin A, Munter E, Wang E, Kelly S, Allegood JC, Liu Y, Peng Q, Ramaraju H, Sullards MC, Cabot M, Merrill AH Jr (2006) Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim Biophys Acta 1758(12):1864–1884
Podbielska M, Levery SB, Hogan EL (2011) The structural and functional role of myelin fast-migrating cerebrosides: pathological importance in multiple sclerosis. Clin Lipidol 6(2):159–179
Lingwood D, Simons K (2010) Lipid rafts as a membrane-organizing principle. Science 327(5961):46–50
Hannun YA, Obeid LM (2008) Principles of bioactive lipid signalling: lessons from sphingolipids. Natl Rev Mol Cell Biol 9(2):139–150
Fyrst H, Saba JD (2010) An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol 6(7):489–497
Hannun YA, Obeid LM (2002) The Ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem 277(29):25847–25850
Merrill AH Jr (2002) De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J Biol Chem 277(29):25843–25846
Pewzner-Jung Y, Ben-Dor S, Futerman AH (2006) When do Lasses (longevity assurance genes) become CerS (ceramide synthases)?: Insights into the regulation of ceramide synthesis. J Biol Chem 281(35):25001–25005
Gault CR, Obeid LM, Hannun YA (2010) An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol 688:1–23
Cadena DL, Kurten RC, Gill GN (1997) The product of the MLD gene is a member of the membrane fatty acid desaturase family: overexpression of MLD inhibits EGF receptor biosynthesis. Biochemistry 36(23):6960–6967
D’Angelo G, Polishchuk E, Di Tullio G, Santoro M, Di Campli A, Godi A, West G, Bielawski J, Chuang CC, van der Spoel AC, Platt FM, Hannun YA, Polishchuk R, Mattjus P, De Matteis MA (2007) Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide. Nature 449(7158):62–67
Hanada K, Kumagai K, Yasuda S, Miura Y, Kawano M, Fukasawa M, Nishijima M (2003) Molecular machinery for non-vesicular trafficking of ceramide. Nature 426(6968):803–809
Hanada K, Kumagai K, Tomishige N, Yamaji T (2009) CERT-mediated trafficking of ceramide. Biochim Biophys Acta 1791(7):684–691
van Meer G, Holthuis JC (2000) Sphingolipid transport in eukaryotic cells. Biochim Biophys Acta 1486(1):145–170
Halter D, Neumann S, van Dijk SM, Wolthoorn J, de Maziere AM, Vieira OV, Mattjus P, Klumperman J, van Meer G, Sprong H (2007) Pre- and post-Golgi translocation of glucosylceramide in glycosphingolipid synthesis. J Cell Biol 179(1):101–115
Marchesini N, Hannun YA (2004) Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochem Cell Biol 82(1):27–44
Quintern LE, Schuchman EH, Levran O, Suchi M, Ferlinz K, Reinke H, Sandhoff K, Desnick RJ (1989) Isolation of cDNA clones encoding human acid sphingomyelinase: occurrence of alternatively processed transcripts. EMBO J 8(9):2469–2473
Duan RD (2006) Alkaline sphingomyelinase: an old enzyme with novel implications. Biochim Biophys Acta 1761(3):281–291
Qin J, Berdyshev E, Goya J, Natarajan V, Dawson G (2010) Neurons and oligodendrocytes recycle sphingosine 1-phosphate to ceramide: significance for apoptosis and multiple sclerosis. J Biol Chem 285(19):14134–14143
Kilkus JP, Goswami R, Dawson SA, Testai FD, Berdyshev EV, Han X, Dawson G (2008) Differential regulation of sphingomyelin synthesis and catabolism in oligodendrocytes and neurons. J Neurochem 106(4):1745–1757
Boudker O, Futerman AH (1993) Detection and characterization of ceramide-1-phosphate phosphatase activity in rat liver plasma membrane. J Biol Chem 268(29):22150–22155
Shinghal R, Scheller RH, Bajjalieh SM (1993) Ceramide 1-phosphate phosphatase activity in brain. J Neurochem 61(6):2279–2285
Van Overloop H, Denizot Y, Baes M, Van Veldhoven PP (2007) On the presence of C2-ceramide in mammalian tissues: possible relationship to etherphospholipids and phosphorylation by ceramide kinase. Biol Chem 388(3):315–324
Hiraoka M, Abe A, Shayman JA (2002) Cloning and characterization of a lysosomal phospholipase A2, 1-O-acylceramide synthase. J Biol Chem 277(12):10090–10099
Spiegel S, Milstien S (2003) Sphingosine-1-phosphate: an enigmatic signalling lipid. Natl Rev Mol Cell Biol 4(5):397–407
el Bawab S, Mao C, Obeid LM, Hannun YA (2002) Ceramidases in the regulation of ceramide levels and function. Subcell Biochem 36:187–205
Momoi T, Ben-Yoseph Y, Nadler HL (1982) Substrate-specificities of acid and alkaline ceramidases in fibroblasts from patients with Farber disease and controls. Biochem J 205(2):419–425
Sun W, Xu R, Hu W, Jin J, Crellin HA, Bielawski J, Szulc ZM, Thiers BH, Obeid LM, Mao C (2008) Upregulation of the human alkaline ceramidase 1 and acid ceramidase mediates calcium-induced differentiation of epidermal keratinocytes. J Invest Dermatol 128(2):389–397
Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman R, Collier C, Zhang M, Satin LS, Merrill AH Jr, Milstien S, Spiegel S (2005) SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem 280(44):37118–37129
Le Stunff H, Peterson C, Liu H, Milstien S, Spiegel S (2002) Sphingosine-1-phosphate and lipid phosphohydrolases. Biochim Biophys Acta 1582(1–3):8–17
Rivera J, Proia RL, Olivera A (2008) The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 8(10):753–763
Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, Camerer E, Zheng YW, Huang Y, Cyster JG, Coughlin SR (2007) Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 316(5822):295–298
Venkataraman K, Lee YM, Michaud J, Thangada S, Ai Y, Bonkovsky HL, Parikh NS, Habrukowich C, Hla T (2008) Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res 102(6):669–676
Murata N, Sato K, Kon J, Tomura H, Yanagita M, Kuwabara A, Ui M, Okajima F (2000) Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J 352(Pt 3):809–815
Berdyshev EV, Gorshkova IA, Garcia JG, Natarajan V, Hubbard WC (2005) Quantitative analysis of sphingoid base-1-phosphates as bisacetylated derivatives by liquid chromatography-tandem mass spectrometry. Anal Biochem 339(1):129–136
Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG (2005) Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309(5741):1735–1739
Ito K, Anada Y, Tani M, Ikeda M, Sano T, Kihara A, Igarashi Y (2007) Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes. Biochem Biophys Res Commun 357(1):212–217
Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427(6972):355–360
Takabe K, Paugh SW, Milstien S, Spiegel S (2008) “Inside-out” signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 60(2):181–195
Anada Y, Igarashi Y, Kihara A (2007) The immunomodulator FTY720 is phosphorylated and released from platelets. Eur J Pharmacol 568(1–3):106–111
Sato K, Malchinkhuu E, Horiuchi Y, Mogi C, Tomura H, Tosaka M, Yoshimoto Y, Kuwabara A, Okajima F (2007) Critical role of ABCA1 transporter in sphingosine 1-phosphate release from astrocytes. J Neurochem 103(6):2610–2619
Maceyka M, Milstien S, Spiegel S (2007) Measurement of mammalian sphingosine-1-phosphate phosphohydrolase activity in vitro and in vivo. Methods Enzymol 434:243–256
Breslow DK, Weissman JS (2010) Membranes in balance: mechanisms of sphingolipid homeostasis. Mol Cell 40(2):267–279
Singh I, Pahan K, Khan M, Singh AK (1998) Cytokine-mediated induction of ceramide production is redox-sensitive. Implications to proinflammatory cytokine-mediated apoptosis in demyelinating diseases. J Biol Chem 273(32):20354–20362
Spiegel S, Milstien S (2002) Sphingosine 1-phosphate, a key cell signaling molecule. J Biol Chem 277(29):25851–25854
Vartanian T, Dawson G, Soliven B, Nelson DJ, Szuchet S (1989) Phosphorylation of myelin basic protein in intact oligodendrocytes: inhibition by galactosylsphingosine and cyclic AMP. Glia 2(5):370–379
Chalfant CE, Spiegel S (2005) Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling. J Cell Sci 118(Pt 20):4605–4612
Irie F, Hirabayashi Y (1998) Application of exogenous ceramide to cultured rat spinal motoneurons promotes survival or death by regulation of apoptosis depending on its concentrations. J Neurosci Res 54(4):475–485
Wheeler D, Bandaru VV, Calabresi PA, Nath A, Haughey NJ (2008) A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain 131(Pt 11):3092–3102
Kroesen BJ, Pettus B, Luberto C, Busman M, Sietsma H, de Leij L, Hannun YA (2001) Induction of apoptosis through B-cell receptor cross-linking occurs via de novo generated C16-ceramide and involves mitochondria. J Biol Chem 276(17):13606–13614
Marchesini N, Luberto C, Hannun YA (2003) Biochemical properties of mammalian neutral sphingomyelinase 2 and its role in sphingolipid metabolism. J Biol Chem 278(16):13775–13783
Kitatani K, Idkowiak-Baldys J, Hannun YA (2008) The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal 20(6):1010–1018
Dodge JC, Clarke J, Treleaven CM, Taksir TV, Griffiths DA, Yang W, Fidler JA, Passini MA, Karey KP, Schuchman EH, Cheng SH, Shihabuddin LS (2009) Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease. Exp Neurol 215(2):349–357
Kuemmel TA, Schroeder R, Stoffel W (1997) Light and electron microscopic analysis of the central and peripheral nervous systems of acid sphingomyelinase-deficient mice resulting from gene targeting. J Neuropathol Exp Neurol 56(2):171–179
Futerman AH, van Meer G (2004) The cell biology of lysosomal storage disorders. Natl Rev Mol Cell Biol 5(7):554–565
Bielawska A, Crane HM, Liotta D, Obeid LM, Hannun YA (1993) Selectivity of ceramide-mediated biology. Lack of activity of erythro-dihydroceramide. J Biol Chem 268(35):26226–26232
Brockman HL, Momsen MM, Brown RE, He L, Chun J, Byun HS, Bittman R (2004) The 4,5-double bond of ceramide regulates its dipole potential, elastic properties, and packing behavior. Biophys J 87(3):1722–1731
Contreras FX, Basanez G, Alonso A, Herrmann A, Goni FM (2005) Asymmetric addition of ceramides but not dihydroceramides promotes transbilayer (flip-flop) lipid motion in membranes. Biophys J 88(1):348–359
Stiban J, Fistere D, Colombini M (2006) Dihydroceramide hinders ceramide channel formation: Implications on apoptosis. Apoptosis 11(5):773–780
Le Stunff H, Galve-Roperh I, Peterson C, Milstien S, Spiegel S (2002) Sphingosine-1-phosphate phosphohydrolase in regulation of sphingolipid metabolism and apoptosis. J Cell Biol 158(6):1039–1049
Graf C, Niwa S, Muller M, Kinzel B, Bornancin F (2008) Wild-type levels of ceramide and ceramide-1-phosphate in the retina of ceramide kinase-like-deficient mice. Biochem Biophys Res Commun 373(1):159–163
Kim S, Steelman AJ, Zhang Y, Kinney HC, Li J (2012) Aberrant upregulation of astroglial ceramide potentiates oligodendrocyte injury. Brain Pathol 22(1):41–57
Schwarz A, Futerman AH (1997) Distinct roles for ceramide and glucosylceramide at different stages of neuronal growth. J Neurosci 17(9):2929–2938
Mitoma J, Ito M, Furuya S, Hirabayashi Y (1998) Bipotential roles of ceramide in the growth of hippocampal neurons: promotion of cell survival and dendritic outgrowth in dose- and developmental stage-dependent manners. J Neurosci Res 51(6):712–722
Miron VE, Schubart A, Antel JP (2008) Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 274(1–2):13–17
Nair A, Frederick TJ, Miller SD (2008) Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci 65(17):2702–2720
Miller RH, Mi S (2007) Dissecting demyelination. Nat Neurosci 10(11):1351–1354
Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B, Reuschel R, Beerli C, Schwartz M, Billich A (2007) Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 323(2):469–475
Sorensen SD, Nicole O, Peavy RD, Montoya LM, Lee CJ, Murphy TJ, Traynelis SF, Hepler JR (2003) Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol Pharmacol 64(5):1199–1209
Wu YP, Mizugishi K, Bektas M, Sandhoff R, Proia RL (2008) Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease. Hum Mol Genet 17(15):2257–2264
Hagen N, Van Veldhoven PP, Proia RL, Park H, Merrill AH Jr, van Echten-Deckert G (2009) Subcellular origin of sphingosine 1-phosphate is essential for its toxic effect in lyase-deficient neurons. J Biol Chem 284(17):11346–11353
Kulakowska A, Zendzian-Piotrowska M, Baranowski M, Kononczuk T, Drozdowski W, Gorski J, Bucki R (2010) Intrathecal increase of sphingosine 1-phosphate at early stage multiple sclerosis. Neurosci Lett 477(3):149–152
Pebay A, Toutant M, Premont J, Calvo CF, Venance L, Cordier J, Glowinski J, Tence M (2001) Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades. Eur J Neurosci 13(12):2067–2076
Brinkmann V (2009) FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 158(5):1173–1182
Delgado A, Casas J, Llebaria A, Abad JL, Fabrias G (2007) Chemical tools to investigate sphingolipid metabolism and functions. ChemMedChem 2(5):580–606
Delgado A, Casas J, Llebaria A, Abad JL, Fabrias G (2006) Inhibitors of sphingolipid metabolism enzymes. Biochim Biophys Acta 1758(12):1957–1977
Radin NS (2003) Killing tumours by ceramide-induced apoptosis: a critique of available drugs. Biochem J 371(Pt 2):243–256
Triola G, Fabrias G, Casas J, Llebaria A (2003) Synthesis of cyclopropene analogues of ceramide and their effect on dihydroceramide desaturase. J Org Chem 68(26):9924–9932
Inokuchi J, Usuki S, Jimbo M (1995) Stimulation of glycosphingolipid biosynthesis by L-threo-1-phenyl-2-decanoylamino-1-propanol and its homologs in B16 melanoma cells. J Biochem 117(4):766–773
Andrieu-Abadie N, Jaffrezou JP, Hatem S, Laurent G, Levade T, Mercadier JJ (1999) L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation. Faseb J 13(12):1501–1510
Liu B, Andrieu-Abadie N, Levade T, Zhang P, Obeid LM, Hannun YA (1998) Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J Biol Chem 273(18):11313–11320
Zemann B, Kinzel B, Muller M, Reuschel R, Mechtcheriakova D, Urtz N, Bornancin F, Baumruker T, Billich A (2006) Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 107(4):1454–1458
Kovarik JM, Hartmann S, Bartlett M, Riviere GJ, Neddermann D, Wang Y, Port A, Schmouder RL (2007) Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects. Biopharm Drug Dispos 28(2):97–104
Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poulton S, Milstien S, Kohama T, Spiegel S (2000) Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem 275(26):19513–19520
Kahan BD, Karlix JL, Ferguson RM, Leichtman AB, Mulgaonkar S, Gonwa TA, Skerjanec A, Schmouder RL, Chodoff L (2003) Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation 76(7):1079–1084
Budde K, Schmouder RL, Nashan B, Brunkhorst R, Lücker PW, Mayer T, Brookman L, Nedelman J, Skerjanec A, Bohler T, Neumayer HH (2003) Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am J Transplant 3(7):846–854
Lee CW, Choi JW, Chun J (2010) Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis. Arch Pharm Res 33(10):1567–1574
Fujino M, Funeshima N, Kitazawa Y, Kimura H, Amemiya H, Suzuki S, Li XK (2003) Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 305(1):70–77
Webb M, Tham CS, Lin FF, Lariosa-Willingham K, Yu N, Hale J, Mandala S, Chun J, Rao TS (2004) Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 153(1–2):108–121
Kataoka H, Sugahara K, Shimano K, Teshima K, Koyama M, Fukunari A, Chiba K (2005) FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2(6):439–448
Balatoni B, Storch MK, Swoboda EM, Schonborn V, Koziel A, Lambrou GN, Hiestand PC, Weissert R, Foster CA (2007) FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 74(5):307–316
Miron VE, Hall JA, Kennedy TE, Soliven B, Antel JP (2008) Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod. Am J Pathol 173(4):1143–1152
Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP (2008) FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 63(1):61–71
Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387–401
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362(5):402–415
Acknowledgments
We gratefully acknowledge financial support from the National Multiple Sclerosis Society (NMSS, NY, USA; Award #RG3473), and partial support from NINDS/NIH (NS 115666) (to ELH); from Multiple Sclerosis International Federation (Du Pré Grant) (to MP). The authors thank Mrs. Katarzyna Izydorczyk for her skillful assistance with Figures preparation. We apologize to those authors whose work we were unable to cite because of space limitations.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Special Issue: In honour of Bob Leeden.
Rights and permissions
About this article
Cite this article
Podbielska, M., Krotkiewski, H. & Hogan, E.L. Signaling and Regulatory Functions of Bioactive Sphingolipids as Therapeutic Targets in Multiple Sclerosis. Neurochem Res 37, 1154–1169 (2012). https://doi.org/10.1007/s11064-012-0728-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-012-0728-y